Site USSUB1007 — Homewood, Alabama

Site USSUB1007 is a clinical research site located in Homewood, Alabama, United States 35209.

Crixeo Clinical Trials Trust Score: 9/100 (FAILING). This profile has not yet been claimed by the site owner.

Site USSUB1007 has participated in 1 clinical trials.

Therapeutic areas: Prostate Cancer, Castration-resistant Prostate Cancer, Metastatic Prostate Cancer.

Sponsors: Astellas Pharma Global Development, Inc..

Is this your site?

Is this your site? Claim your profile and control the information sponsors and patients see.

Other research sites in Homewood

Browse all research sites in Alabama · View every site in Homewood

• University of Alabama at Birmingham 1
• Urology Centers of Alabama
• Alabama Neurology Associates
• Research Site
• Urology Centers Of Alabama Pc
• GSK Investigational Site
• Pfizer Investigational Site
• Central Alabama Research
• Novartis Investigative Site
• Urology Center of Alabama
• Warner Chilcott Investigational Site
• Local Institution - 1029

Sponsor Feasibility Report

Trust Score: 9/100. Verification status: Not yet accredited. Patient reviews: 0. Complaints: 0.

Frequently Asked Questions

What is the Trust Score for Site USSUB1007?

Site USSUB1007 has a Crixeo Trust Score of 9/100 (FAILING). Trust Scores reflect trial volume, sponsor diversity, patient reviews, address verification, and accreditation status.

How many clinical trials has Site USSUB1007 conducted?

Site USSUB1007 has 1 clinical trials on record. Their work covers Prostate Cancer, Castration-resistant Prostate Cancer, Metastatic Prostate Cancer.

Is Site USSUB1007 accredited by Crixeo Clinical Trials?

Site USSUB1007 has not yet obtained Crixeo Accreditation. Site owners can claim their profile and apply for accreditation to improve visibility with sponsors and patients.

Can I submit a review or complaint about Site USSUB1007?

Yes. Patients and trial participants can submit reviews and file complaints directly on this profile page. All submissions are reviewed before publication.